Complete human monoclonal IgG4lambda specific for CTLA-4 and uses thereof for detection of soluble CTLA-4 and isolation of regulatory cells
OwnerLi-Te CHIN, Shu-Ching HSUinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases.
Claims15
A composition for detecting human CTLA-4, said composition comprising:
- (a) a CTLA-4 antagonist or agonist, wherein said antagonist comprises an antibody or an antigen-binding fragment thereof and said agonist comprises CD80 or an CTLA-4-binding fragment thereof;
- and
- (b) a CTLA-4 non-blocking agent that recognizes the extracellular domain of CTLA-4, wherein said CTLA-4 non-blocking agent comprises an antibody or an antigen-binding fragment thereof.
A method of isolating regulatory T cells from human samples, said method comprising:
- (a) contacting a population of suspended cells in a sample with a CTLA-4 non-blocking agent that recognizes the extracellular domain of CTLA-4, wherein said CTLA-4 non-blocking agent is non-immunogenic in a human and comprises an antibody or an antigen-binding fragment thereof;
- and
- (b) selecting cells that bind to the CTLA-4 non-blocking agent, wherein the selected cells are enriched for regulatory T cells.
A method for increasing the activation of T cells in a human subject comprising administrating an effective amount of a functional derivative of the CTLA-4 non-blocking agent, wherein the functional derivative of the CTLA-4 non-blocking agent binds to the sequences consisting SEQ ID NO:1.
Dependencies are inferred from the claim text.